ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2021
Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Resistance training improves functional capacities in women with multiple sclerosis: a randomized control trial.BMC neurology · 2024Trial
- Dysregulation of ferroptosis-related plasma biomarkers in treatment-free patients with relapsing-remitting multiple sclerosis in clinical remission: a case-control study.Acta neurologica Belgica · 2026Article
- Article
- Is Obesity a Modifiable Risk Factor in Multiple Sclerosis? Mechanistic Insights into Neuroinflammation and Oxidative Damage.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- An assessment of an antioxidative status in patients with multiple sclerosis using standard biochemical analyses.Journal of medical biochemistry · 2025Article
- The impact of oxidative stress on symptoms associated with multiple sclerosis.Scientific reports · 2025Article
- Elevated Oxidative Stress in Patients with Coexisting Multiple Sclerosis and Migraine: A Cross-Sectional Study.Antioxidants (Basel, Switzerland) · 2025Article
- Parkia biglobosa Jacq. (Locust Bean) leaves and seeds extracts attenuates diabetic-linked cognitive dysfunction in streptozotocin-induced male wistar rats.Metabolic brain disease · 2024Article
- Circulatory Indicators of Lipid Peroxidation, the Driver of Ferroptosis, Reflect Differences between Relapsing-Remitting and Progressive Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Oxidative Stress Markers in Multiple Sclerosis.International journal of molecular sciences · 2024Review
- Circulating Fatty Acids Associate with Metabolic Changes in Adolescents Living with Obesity.Biomedicines · 2024Article
- The Role of Gut-derived Short-Chain Fatty Acids in Multiple Sclerosis.Neuromolecular medicine · 2024Review
- Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing-Remitting Multiple Sclerosis.Antioxidants (Basel, Switzerland) · 2023Article
- Chelation Therapy Associated with Antioxidant Supplementation Can Decrease Oxidative Stress and Inflammation in Multiple Sclerosis: Preliminary Results.Antioxidants (Basel, Switzerland) · 2023Article
- The Pathophysiological Changes and Clinical Effects of Tetramethylpyrazine in ICR Mice with Fluoride-Induced Hepatopathy.Molecules (Basel, Switzerland) · 2023Article
- Evaluation of Selected Oxidant/Antioxidant Parameters in Patients with Relapsing-Remitting Multiple Sclerosis Undergoing Disease-Modifying Therapies.Antioxidants (Basel, Switzerland) · 2022Article
- Probiotics and Commensal Gut Microbiota as the Effective Alternative Therapy for Multiple Sclerosis Patients Treatment.International journal of molecular sciences · 2022Review
- Nitrosative Stress Molecules in Multiple Sclerosis: A Meta-Analysis.Biomedicines · 2021Review
- An Exploratory Cross-Sectional Study of the Association Between Regular Cigarette Smoking and Level of Disability, Hand Dexterity, Cognitive Impairment, Fatigue, and Markers of Oxidative Stress in Male Patients With Relapsing-Remitting Multiple Sclerosis.American journal of men's healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of our study was to analyze oxidative stress (OS) markers in multiple sclerosis (MS) patients during relapse and remission and to evaluate the effects of corticosteroid relapse treatment on oxidative status, and also to determine possible relationship between OS markers and relapse disability recovery after corticosteroid treatment.
methodsOur study included 118 MS patients, (59 relapse/59 remission) 70 females and 48 males, mean age 40.2 ± 9.4 years, and 88 matched healthy controls. Undergoing disease-modifying therapy (DMT) was present in 30.5% of relapse and 88% of remission MS patients. We analyzed in plasma/serum the following: pro-oxidative-antioxidative balance (PAB), nitrates and nitrites (NO
resultsBetter clinical recovery after relapse treatment was associated with increased baseline SOD, decreased AOPP, and ongoing DMT (all p < 0.05). There was no difference between OS markers in relapse and remission. MS patients had higher MDA, NO
conclusionIncreased baseline antioxidative activity of SOD and decreased baseline levels of pro-oxidant AOPP along with ongoing DMT were related to better clinical recovery after corticosteroid relapse treatment. Increase of pro-oxidants and antioxidant enzyme activity in relapse and remission confirms ongoing oxidative injury irrelevant of MS clinical presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.